A Study of DS-1471a In Subjects With Advanced Solid Tumors
Terminated · Phase 1 · NCT06074705
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $571,538
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 17
About the trial
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Tested
- DS-1471a (drug)
- Dates
- Started 2023-08-04; completion 2025-07-29
- Results posted
- Not yet
This first-in-human (FIH) study will assess the safety, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of DS-1471a in participants with advanced or metastatic solid tumors.
From ClinicalTrials.gov, last updated 2025-08-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $571,538 in research payments for this study in 2025 (91 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Ben George, M.D. Medical Oncology · Rochester, MN
- Emerson Y. Chen, MD Hematology & Oncology · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Florida Cancer Specialists and Research Institute Sarasota Cattlemen $337,712
- Ohsu Hospital and Clinics, OR $83,172
- Medical College of Wisconsin $75,327
- Froedtert Memorial Lutheran Hospital, WI $75,327
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.